1. Karyopharm to present at Jefferies Global Healthcare Conference on June 5, 2025. 2. XPOVIO® approved in the U.S. for multiple oncology indications. 3. Karyopharm focuses on unmet medical needs in various cancers.
The announcement of Karyopharm's upcoming presentation is likely to raise investor interest. Historically, similar events have often resulted in stock price appreciation, especially for companies with promising drug pipelines.
The upcoming presentation at a major healthcare conference suggests potential for new investor engagement and interest in KPTI's pipeline, which might result in a positive impact on stock valuation.
The impact from this event will likely be immediate due to investor reactions. Other similar conference presentations typically affect stocks in the days leading up to and immediately following the event.
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m. ET in New York, NY.
A live webcast of the presentation along with accompanying slides can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis.
Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
SOURCE Karyopharm Therapeutics Inc.